Evaluation of the ‘Colli-Pee’, a first-void urine collection device for self-sampling at home for the detection of sexually transmitted infections, versus a routine clinic-based urine collection in a one-to-one comparison study design: efficacy and acceptability among MSM in Belgium

Irithe De Baetselier,1 Hilde Smet,1 Said Abdellati,1 Bénedict De Deken,1 Vicky Cuylaerts,1 Thijs Reyniers,2 Bea Vuylsteke,2 Tania Crucitti1

ABSTRACT

Objectives Pre-exposure prophylaxis (PrEP) users are screened bi-annual for sexually transmitted infections (STIs). A novel device, called the Colli-Pee, collects first-void urine in a standardised way and the collector tube can be easily delivered by regular post to a certified laboratory. The aim of the study was a one-to-one comparison between the STI test results obtained with the urine collected in the clinic, versus urine collected at home in a real-life setting by Men who have Sex with Men (MSM) in Belgium. The user-friendliness and acceptability of the Colli-Pee device by the users was also evaluated.

Design A single-site nested substudy in a prospective PrEP demonstration project (Be-PrEP-ared) among MSM in Belgium.

Participants A total of 473 home-based samples from 213 MSM were received with a mean age of 38.5 years.

Interventions Participants were requested to collect a urine sample at home using the Colli-Pee device and to send it to the laboratory via regular mail.

Primary and secondary outcome measures The presence of Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Mycoplasma genitalium (MG) and Trichomonas vaginalis (TV) was determined using molecular amplification assays. Agreement between test results of samples collected at the clinic and collected at home were evaluated using Cohen’s kappa statistic. Results: TV was not detected. A very good to almost perfect agreement was found for CT, NG and MG of κ=0.75, 0.87 and 0.85, respectively. Using the Colli-Pee device only one low positive CT and two MG infections were detected, however, three additional CT, two NG and six MG infections were detected.

Conclusions The Colli-Pee device is a feasible and convenient way to collect urine at home for STI testing. This may be particularly relevant for populations that need frequent STI testing, such as PrEP users and patients who prefer home-sampling.

Trial registration number NCT02552914; Pre-results.

Strengths and limitations of this study

- The study was designed as such to provide real-world experience concerning home-based sampling for sexually transmitted infection (STI) detection including shipment by post among pre-exposure prophylaxis (PrEP) users.
- Home-based and clinic-based samples were processed and analysed using the same procedures and laboratory staff was blinded for the results of the matching sample.
- The study was performed among Men who have Sex with Men PrEP users who have a high prevalence of STIs.
- Our main limitation is that home-based samples were not taken on the same day as clinic-based sampling and participants could have become positive during that window period.
- Another limitation of the study is that the temperature during transportation of home-based samples to the clinic was not monitored.

INTRODUCTION

According to the WHO’s Global Health Sector Strategy on sexually transmitted infections (STIs) 2016–2021, early diagnosis and linkage to treatment are one of the key elements for preventing further transmission of STIs.1 Currently, first-void urine is still favoured as the sample of choice for the detection of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) in men, using nucleic acid amplification tests (NAATs).2–4 In general, a regular urine container is used to collect the first-void urine sample, but the collected volume of urine is not standardised. Furthermore, this
type of container is less convenient for postal delivery to the laboratory. Another sponged-based device (UriSWAB, Copan Diagnostics, Brescia, Italy) has been suggested as an alternative for postal delivery of urine. However, this device only holds 2 mL of urine and does not guarantee that only first-void urine is collected.4 5 The (Conformité Européene (CE) labelled Colli-Pee device (Novosanis, Belgium), provides a clean and standardised solution to the above-mentioned issues as it efficiently captures first-void urine (20 mL) without interruption of the urine flow and allows the samples to be sent by post (figure 1). The Colli-Pee device is currently used for the detection of human papilloma virus and several urological cancers for which collection of first-void urine is essential.6 7 In the field of STIs, a standardised first-void urine study reported that the organism load of CT is maximal in the first 4–5 mL and that the performance of diagnostic tests improved when using only first-void urine.8 9

Although pre-exposure prophylaxis (PrEP) is becoming crucial in HIV prevention, recent reviews of real-world PrEP demonstration studies showed that PrEP is associated with increased diagnoses of STIs in Men who have Sex with Men (MSM).10 11 Consequently, current guidelines recommend a biannual screening of STIs in PrEP users because of their high-risk behaviour.12 13

In order to facilitate the patient flow during follow-up visits by PrEP users, and prompt treatment of STIs, home-based collection of first-void urine could be sent to the laboratory by regular mail for STI detection before the scheduled visit. STI results may then be available at the time of the physician consultation and in the case of a detected STI also immediately treated, limiting the risk of further transmission.

The objectives of this study were to compare the results of the molecular detection of several STIs using the Colli-Pee device versus a sample obtained in the clinic, the use and acceptability of the Colli-Pee device and its convenience for shipment by regular mail. To assess these objectives, a nested substudy was performed among MSM who participated in a Belgian PrEP demonstration cohort.14

METHODS
The evaluation was undertaken as a substudy of Be-PrEP-ared, a PrEP demonstration study among MSM at high risk for HIV in Belgium.

The main study
The Be-PrEP-ared project (EudraCTn°: 5015–00005437) was a phase 3, single-site, open-label prospective cohort study where 200 MSM at high risk of acquiring HIV were asked to participate in the project and to take PrEP daily or event-driven. Detailed study methods are described elsewhere.14 Participants were tested for NG, CT, Myco-plasma genitalium (MG) and Trichomonas vaginalis (TV) at baseline and every 3 months. Detection of these STIs was performed at the three biological sites: urethra, anorectum and pharynx. During each study visit, participants collected urine in two urine containers at the clinic as per the following instructions: urinate in the first container up to the marked line at approximately 20 mL, afterwards complete the second cup with no restrictions. Urine in the first container (hereafter the clinic-based sample) was weighed and thereafter stored refrigerated until analysis that took place within 48 hours. Urine in the second container was used to detect proteinuria.

Laboratory procedures
In the first instance, CT/NG detection was performed using the Abbott Real Time (RT) CT/NG assay (DNA extraction and sample preparation using Abbott m2000sp and the Abbott m2000rt system for amplification and detection of CT/NG [Abbott Molecular Des Plaines, Illinois, USA]) according to manufacturer’s instructions. The remainder of the urine and DNA extracts were stored at −80°C. In the case of positivity, the same DNA extracts were tested by in-house real time (RT)-PCR assays for CT and/or NG, both based on previously published primer sets.15 16 A sample was considered positive when positive in both the Abbott and the in-house RT-PCR. An initial positive Abbott assay result followed by a negative confirmatory NAAT result was defined as ‘not confirmed’. Inhibition of the NAAT according to the Abbott assay was defined as ‘inhibition’.

The same DNA extracts were used for further testing. MG was detected and reported using an accredited in-house RT-PCR that targets the pdhD-gene and in addition the DiaMGTV multiplex kit (Diagenode diagnostics, Seraing, Belgium) that detects MG and TV simultaneously was used for TV detection. The results for MG of the DiaMGTV multiplex kit were not used for reporting purposes and are only provided for information only. No further confirmation of TV took place.

The Colli-Pee substudy
At the baseline visit of the Be-PrEP-ared study, participants were asked consent to participate in this substudy. After signing the informed consent form, they received a Colli-Pee device and a prepaid envelope. They were instructed to collect first-void urine the next day at home using the Colli-Pee device (the home-based sample), to document the date and time of collection and to send the collector tube filled with urine back to the laboratory by regular post, using the prepaid envelope. On receipt in the laboratory, the urine was weighed, stored refrigerated...
(2°C–8°C) and CT, NG, MG, TV was detected using the same NAATs within 48 hours. The urine and DNA extracts’ remnants were stored at −80°C. The quantity of human cells was measured at baseline using a human Endogenous Retrovirus-3 (ERV-3) quantitative PCR on the paired clinic- and home-based samples.

The lab technicians were blinded for the results obtained for the clinic-based sample. In addition, the result of the home-based sample was not disclosed to the physician or participant.

During the next visit, which took place within 14 days after baseline, participants were asked to complete a small survey (five questions only) on the user-friendliness and willingness to use the Colli-Pee device (acceptability). Two questions documenting their opinion (likes-dislikes) of the Colli-Pee device were open-ended.

At follow-up month 6 and month 18 of the study, Colli-Pee devices were again distributed to those who agreed to participate and the survey was repeated at month 18 (results unreported).

Patient and public involvement
Patients were not involved in the Colli-Pee substudy. Patients were not invited to comment on the study design and were not consulted to develop patient relevant outcomes or interpret the results. Patients were not invited to contribute to the writing or editing of this document for readability or accuracy.

Statistical analysis
The agreement of the results of the molecular assays using each of the two sampling methods was assessed by the use of Cohen’s kappa statistic and percent agreement. Samples that were not confirmed were coded as negative samples for the calculation of the agreement. The agreement of volume of urine collected and the agreement of concentration of human DNA in both sampling methods was assessed by using a t-test. A p-value of <0.05 was considered statistically significant. Both analyses were performed using STATA V.15.0.

A descriptive analysis was made of the results of the self-administered questionnaire on the acceptability and user-friendliness of the Colli-Pee device.

RESULTS
Demographics
The main study took place at the Institute of Tropical Medicine, Antwerp, Belgium from September 2015 until May 2018. Of the 219 participants who were screened for eligibility into the main study, six participants did not consent to the Colli-Pee substudy. All participants who consented to the substudy were MSM and three identified themselves as transwomen. The mean age of the participants was 38.5 years (IQR 32–44). A total of 473 home-based samples from 213 participants were received. Two home-based samples could not be linked to the corresponding clinic-based sample and were therefore excluded, bringing the total number to 471. As shown in Table 1, the number of home-based samples received at the laboratory declined over time.

Although the participants were instructed to report the urine collection date and hour on the collection device, only 72.8% (343/471) were labelled with collection date. Most of the home-based samples (79.6%) were taken within 2 days after the clinic-based sample and 3.8% were taken after 20 days (13/343) (median 1 day; min-max: 0–70 days). The median time between the collection of the home-based sample and its reception at the laboratory after postal return was 5 days (min-max: 0–27 days), 72.9% arrived at the laboratory within those 5 days, an additional 25.7% within 10 days and five samples were received after 10 days (11, 13, 15, 17 and 27 days, respectively).

Comparison of weight and concentration of human material between both sampling methods
A total of 455 home-based and 423 clinic-based samples were weighed. The mean net weight of the home-based sample was 19.68±2.14 g (95% CI 19.5 to 19.9 g and min-max: 6.81 g to 39.47 g) vs 22.87±13.64 g (95% CI 21.6 g to 24.2 g and min-max: 2.8 g to 86.23 g) for the clinic-based sample (p<0.001).

The quantity of human cells was analysed at baseline only (n=187). In a total of five home-based and one clinic-based sample, ERV could not be detected and these samples were considered as lacking human material. After removal of the paired samples lacking ERV or containing inhibitors, 182 observations could be paired. The mean quantity of the clinic-based sample was 11.3±10³ cells/PCR (95% CI 7.4 to 15.2±10³) and for the home-based sample 14.2±10³ cells/PCR (95% CI 6.8 to 21.5±10³) (p>0.05).

STI results and agreement
Of the 471 home-based samples with a matching visit, six home-based and one clinic-based sample gave inhibition and were excluded from the analysis (n=464). The results are shown in Table 2.

TV was not detected. Percent agreement (Cohen’s kappa coefficient) for CT, NG and MG is 99.1% (0.75); 99.6% (0.87) and 98.3% (0.85), respectively, which indicates substantial agreement for CT and almost perfect agreement for the other two STIs.

Tables 3 and 4 show the discordant results. For some of the home-based samples, the date of collection was unknown so the time between the clinic visit and time of reception at the laboratory is depicted here. A delta cycle

| Kind of visit | Clinic based | Home based (% home-based samples received) |
|--------------|-------------|------------------------------------------|
| Screening    | 218         | 187 (85.8%)                              |
| Month 6      | 191         | 152 (79.6%)                              |
| Month 18     | 179         | 132 (73.7%)                              |
De Baetselier I, et al. BMJ Open 2019;9:e028145. doi:10.1136/bmjopen-2018-028145

To the question of whether they would order an online STI test with self-sampling. Price indications ranged from 0€ (10 participants) to 60€. Most of the participants (89/164) were willing to pay 10–20€.

**DISCUSSION**

Many studies have reported on male self-collected urine versus urethra clinician-collected sampling for STI screening, but ‘real-world’ studies, including sending of home-based urine samples for STI detection in men by post, are sparse. In this study, we showed that the Colli-Pee collection device is a valuable and reliable method for collecting first-void urine for STI detection in MSM in Belgium, and that the collector can be shipped by regular post. Compared with the clinic-based sample, a total of three STIs (one CT and two MG infections) were not detected in the home-based sample. However, 11 additional infections were found in home-based samples collected with the Colli-Pee device (3 CT, 2 NG and 6 MG infections). This high number of additional STIs could be explained by the fact that first-void urine contains more DNA/RNA than mid-stream and, as a consequence, should still be used for STI detection. Indeed, we showed that using the Colli-Pee device first-void urine was collected in a more standardised way compared with the clinic-based samples (p<0.001). Also, more human cells were collected in the home-based samples, however statistical significance was lacking. The fact that participants could become positive during the time in between sampling points is one of our main limitations and cannot be ignored. Preliminary data of the Be-PrEP-ared study showed high-incidence estimates after twelve months of the main Be-PrEP-ared study for urethral CT/NG and MG: 11.5, 5.1 and 6.9 incidence rate per 100 person-years, respectively.

Nevertheless, the most important observation is that only one *Chlamydia* positive result was missed. The DC value of the Abbott assay performed on that clinic-based sample highlighted the low bacterial load of that infection; in addition, transportation at room temperature for 2 days could have induced DNA degradation.

The WHO underlines the importance of integrating point-of-care assays (POCTs) including innovative delivery options such as self-testing. Unfortunately, to our knowledge, current commercial POCTs for the most important STIs such as CT and NG are still of sub-optimal quality and do not meet the ASSURED criteria that were developed by the WHO STI Diagnostics Initiative. A solution to the unavailability of qualitative POCTs could be internet-accessed STI testing (e-STI testing) which is increasingly available as an alternative to clinic testing all over the world. E-STI testing includes postal self-sampling test kits that are sent to a certified laboratory and web-based delivery of test results. Swab2Know, an online HIV testing project confirmed that e-HIV testing is acceptable and feasible among MSM in Belgium. Commercial online self-sampling services for STIs are now emerging.

---

**Table 2 Sexually transmitted infections results of the home-based and clinic-based urine samples**

| STI (non-LGV) | Clinic-based urine results | Home-based urine result |
|---------------|----------------------------|-------------------------|
| *Chlamydia trachomatis* | Negative 454* | 1 | 455 |
| | Positive 3 | 6 | 9 |
| | Total 457 | 7 | 464 |

| *Neisseria gonorrhoeae* | Negative 455 | 0 | 455 |
| | Positive 2 | 7 | 9 |
| | Total 457 | 7 | 464 |

| *Mycoplasma genitalium* | Negative 431 | 2 | 433 |
| | Positive 6 | 25 | 31 |
| | Total 437 | 27 | 464 |

| *Trichomonas vaginalis* | Negative 464 | 0 | 464 |
| | Positive 0 | 0 | 0 |
| | Total 464 | 0 | 464 |

*Two result were not-confirmed in the clinic-based sample.

---

**Table 3 Sexually transmitted infections that were not detected in home-based urine samples**

| STI | DC value | Ct value in-house | Ct-value S-DiagMGTV | Ct-value RT-PCR (for information only) | Days between collection | Days of transport |
|-----|----------|-------------------|---------------------|---------------------------------------|------------------------|------------------|
| CT  | 1.49     | 33.19             | NA                  | 0                                     | 2                      |
| MG  | NA       | 32.20             | Neg                 | 3                                     | 4                      |
| MG  | NA       | 32.04             | 37.44               | 0                                     | 8                      |

*A different in-house RT-PCR assay was used for CT, NG or MG. Ct, cycle threshold; DC, delta cycle; Max, days between clinic visit and reception of the home-based sample at the laboratory.
over the internet, but evaluation of these services is lacking.

The present study is, however, subject to several limitations. First, we only enrolled Be-PrEP-ared participants and the participation level seriously declined during the study. As a result, our number of CT/NG positives is quite low, which precludes firm conclusions. Second, as mentioned above, home-based samples were not taken on the same day as clinic-based sampling and participants could have become positive during that window period. We also do not know whether participants had urinated 1 hour prior to collection. However, recent data show that the time between micturition is not crucial for the detection of *Chlamydia* in men. Third, we did not monitor the temperature of the transport of home-based samples which could also have an impact on the quality of the samples, however, outside temperature between October 2015 and May 2018 varied between −10°C and 33°C with an average of 11°C.

Fourth, we cannot exclude specimen contamination, however, participants were instructed how to correctly collect the clinic-based and home-based sample. Finally, reporting bias is also not to be excluded. Not all participants who used a Colli-Pee device completed the survey, the additional questions were included at the end of the lengthy main questionnaire of the Be-PrEP-ared study. Besides PrEP users, e-STI testing has the potential to reach those who are most in need and a recent study showed that some higher-risk groups, such as MSM, were more likely to use online services. Many studies have shown that home-based sampling is well accepted and, in fact, is the preferred approach in these groups for STIs. Reasons for choosing home-based sampling were shorter waiting times for results, convenience and less embarrassment. Participants views regarding ordering an online STI test in this study were very positive, 89% would like to order such a kit. The Colli-Pee device was also found to be easy (90.2%) and although hygiene was one of the likes, it also appeared in the dislikes, probably because the need to detach the collector manually can cause leakage of urine. Participants were also concerned regarding possible ecological consequences, although the plastic material is recyclable and can be incinerated into energy.

We demonstrated that postal delivery of home-based collected urine does not influence STI detection and can be used among PrEP users. Subsequently, PrEP users will be able to send first-void urine to the laboratory with the Colli-Pee device 1–2 weeks before their routine PrEP follow-up visit. Results can then be discussed during the physician consultation and followed by treatment and future antimicrobial testing if applicable, decreasing the number of physician visits. Decreasing the number of face-to-face visits will lower the burden on staff workload and healthcare resources. However, future economic evaluations will need to be conducted to prove this statement. E-STI testing could be a promising approach in Belgium to reach patients in hard-to-reach populations and research on this topic should be stimulated. Therefore, future studies to study the acceptability and impact of postal shipment of home-collected material on the performance of STI assays requires additional assessment.

**Table 4** Sexually transmitted infections that were additionally detected in home-based urine samples

| STI   | DC value CT/NG Abbott assay | Ct value in-house RT-PCR for CT, NG or MG* | Ct-value S-DiagMGTV RT-PCR (for information only) | Days between collection | Days of transport |
|-------|-----------------------------|------------------------------------------|------------------------------------------------|------------------------|------------------|
| CT    | 3.99                        | 34.26                                    | NA                                           | 1                      | 2                |
| CT    | 2.68                        | 35.31                                    | NA                                           | 1                      | 6                |
| CT    | 0.27                        | 36.06                                    | NA                                           | 6                      | 4                |
| NG    | 2.93                        | 37.58                                    | NA                                           | 8                      | 4                |
| NG    | 10.08                       | 25.26                                    | NA                                           | 2                      | 6                |
| MG    | NA                          | 31.28                                    | Neg                                          | Max 6                  | Max 6            |
| MG    | NA                          | 31.96                                    | 40.51                                        | 1                      | 2                |
| MG    | NA                          | 28.66                                    | 34.67                                        | Max 3                  | Max 3            |
| MG    | NA                          | 34.58                                    | 38.50                                        | 9                      | 4                |
| MG    | NA                          | 34.23                                    | Neg                                          | 1                      | 5                |
| MG    | NA                          | 32.04                                    | 38.14                                        | Max 3                  | Max 3            |

*A different in-house RT-PCR assay was used for CT, NG or MG.
Ct, cycle threshold; DC, delta cycle; Max, number of days between clinic visit and reception of the home-based sample at the laboratory.

**Author affiliations**

1Department of Clinical Sciences, HIV/STI Reference Laboratory, Institute of Tropical Medicine, Antwerp, Belgium
2Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium

**Acknowledgements** We would like to thank all the participants of the Be-PrEP-ared study who participated in this small study. We also would like to thank Be-PrEP-ared study group but especially Maureen Aerts who was crucial in the performance of STI assays requires additional assessment.

**Contributors** IDB, TC and BV designed the study. TR designed the acceptability survey. IDB performed the statistical analysis and wrote the first draft of the manuscript. HS, BDD, VC and SA performed testing. All authors read the final version of the manuscript and provided comments.
Funding This work was supported by Novosanis who provided the Colli-PeeTM devices and partially paid for the analyses performed on the home-based samples. In addition, a grant was obtained from the Flemish Agency for Innovation and Entrepreneurship to conduct the Be-PrEP-ayed study.

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval The main study was approved by the Institutional Review Board of the Institute of Tropical Medicine and the Ethics Committee of the Antwerp University Hospital. In addition, separate approval for this substudy was obtained by the Institutional Review Board of the Institute of Tropical Medicine (Ref: 1027/15).

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement The data will be made publicly available except for the use and acceptability data as these will be retained at the Institute of Tropical Medicine (ITM), Antwerp due to ethical and privacy concerns. According to the ITM research data sharing policy, only fully anonymised data can be shared publicly. The data can however be made available after approval of a motivated and written request to the ITM at ITMresearchdataaccess@itg.be. The ITM data access committee will verify if the dataset is suitable for obtaining the study objective and assure that confidentiality and ethical requirements are in place.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

REFERENCES

1. WHO. Global health sector strategy on sexually transmitted infections 2016-2021: World Health Organ, 2016.
2. Lanjouw E, Ouborg S, de Vries HJ, et al. 2015 European guideline on the management of Chlamydia trachomatis infections. Int J STD AIDS 2016;27:333–48.
3. Bignell C, Unemo M. 2012 European guideline on the diagnosis and treatment of gonorrhoea in adults. Int J STD AIDS 2013;24:85–92.
4. Lunny C, Taylor D, Hoang L, et al. Use of the uriswab collection device for testing of chlamydia trachomatis and neisseria gonorrhoeae: implications for a postal testing service. Int J STD AIDS 2013;24:477–80.
5. Vorsters A, Van den Bergh J, Micalessi I, et al. Use of the uriswab collection device for the diagnosis of rectal lymphogranuloma venereum and non-lymphogranuloma venereum chlamydia trachomatis infections. Sex Transm Infect 2008;84:273–6.
6. Hopkins MJ, Ashen L, Atidawe F, et al. Validation of a laboratory-developed real-time PCR protocol for detection of chlamydia trachomatis and neisseria gonorrhoeae in urine. Sex Transm Infect 2010;86:207–11.
7. Morré SA, van Valkengoed IG, de Jong A, et al. Evaluation of an enzymatic Chlamydia trachomatis point-of-care rapid assay in Rwanda: the BioChekSwab rapid test. Sex Transm Infect 2016;92:430–2.
8. Wilson E, Free C, Morris TP, et al. A real-time quadruplex PCR assay for the detection of rectal lymphogranuloma venereum and non-lymphogranuloma venereum chlamydia trachomatis infections. Sex Transm Infect 2017;93:S81–8.
9. Wilson E, Free C, Morris TP, et al. Internet-accessed sexually transmitted infection (e-STI) testing and results service: the way forward. J Med Internet Res 2015;17:e213.
10. Mathew T, O’Mahony C, Mallinson H. Shortening the voiding interval for testing of chlamydia trachomatis and Neisseria gonorrhoeae infections. Cochrane Database Syst Rev 2015;CDO11317.
11. De Baetselier I, Mwambarangwe L, Cuylaerts V, et al. Choosing between daily and event-driven pre-exposure prophylaxis: results of a Belgian PrEP demonstration project. J Acquir Immune Defic Syndr 2017;79:186–194.
12. De Baetselier I, Reyniers T, Nöstlinger C, et al. Mailed, home-obtained urine screening: a reliable screening approach for detecting asymptomatic Chlamydia trachomatis infections. J Clin Microbiol 1999;37:976–80.
13. De Baetselier I, Aponte-Gonzalez J, Vigil P, et al. Home-based versus clinic-based specimen collection in the management of Chlamydia trachomatis and Neisseria gonorrhoeae infections. Sex Transm Infect 2008;84:273–6.